Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination regimens, such as Roche / Genentech’s Zelboraf + Cotellic, Novartis’s Tafinlar + Mekinist, and, more recently, Pfizer / Array BioPharma’s Braftovi + Mektovi, are key options for melanoma patients harboring BRAF mutations, while the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb) offer therapeutic options to patients regardless of mutation status. This content explores the key factors driving surveyed U.S. medical oncologists’ prescribing decisions for malignant melanoma.
- What are the current treatment practices in the adjuvant setting and factors influencing the use of BRAF/MEK or anti-PD-1 therapy?
- What is the uptake of immune checkpoint inhibitors and BRAF/MEK inhibitors for the treatment of BRAF-mutation-positive patients?
- How do drug-treatment rates vary across key malignant melanoma patient populations, according to stage of disease and line of therapy?
- What are the drivers and constraints that influence treatment decisions in the unresectable or metastatic setting for select targeted therapies?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of approximately 100 U.S. medical oncologists in March and April 2020.
Key drugs covered: Keytruda, Opdivo ± Yervoy, Zelboraf, Cotellic, Tafinlar, Mekinist, Braftovi, Mektovi, Imlygic.
- Detailed, Expanded Analysis (US)
- Current Treatment: Physician Insights | Malignant Melanoma | US | June 2020
Author(s): Ananya Sadhu, Ph.D; Liseth M Parra, Ph.D
Ananya Sadhu, is an analyst with the oncology team at Decision Resources Group with expertise in multiple oncology indications including pancreatic cancer. Prior to joining Decision Resources Group, Dr. Ananya Sadhu was a postdoctoral fellow at National Centre of Biological Sciences, Bangalore, where she studied the role of chromatin architecture in regulating gene expression in breast cancer. Ananya holds a in Molecular Biology from National Institute of Immunology, New Delhi. She also worked as a Scientific Officer with Arvind Remedies Ltd., a pharmaceutical company, where she coordinated various stages of non-clinical / clinical research activities for drug development of a patented polyherbal formulation.
Liseth M Parra, is an analyst on the Oncology team at Decision Resources Group with an extensive background in oncology research and market analysis. Prior to joining DRG, Liseth generated valuable offerings and comprehensive strategic solutions for leading R&D clinical, commercial, and marketing teams in oncology as a research analyst for Kantar Health and as an independent consultant. Liseth holds a in neurobiology from the University of California, San Diego and completed a postdoctoral fellowship in oncology at the Brigham and Women’s hospital, Harvard Medical School. Liseth supports DRG’s syndicated oncology research offerings, focusing on malignant melanoma disease landscape and forecast analysis.